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Abstract 
The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum 
drug resistance developed from H69 human small cell lung cancer cells with eight 4-
day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A 
recovery period was given between treatments to emulate the cycles of chemotherapy 
given in the clinic. The resistant cell lines were approximately 2-fold resistant to 
cisplatin and oxaliplatin and were cross resistant to both drugs. Platinum resistance 
was not associated with increased cellular glutathione, decreased accumulation of 
platinum or increased DNA repair capacity. The H69 platinum sensitive cells entered 
a lengthy 3 week growth arrest in response to low-level cisplatin or oxaliplatin 
treatment. This is an example of the coordinated response between the cell cycle and 
DNA repair. In contrast the H69CIS200 and H69OX400 cells have an alteration in the 
cell cycle allowing them to rapidly proliferate post drug treatment. The resistant cell 
lines also have many chromosomal rearrangements most of which are not associated 
with the resistant phenotype, suggesting an increase in genomic instability in the 
resistant cell lines. We hypothesised that there was a lack of coordination between the 
 2 
cell cycle and DNA repair in the resistant cell lines allowing proliferation in the 
presence of DNA damage which has created an increase in genomic instability. The 
H69 cells and resistant cell lines have mutant p53 and consequently decrease the 
expression of p21 in response to platinum drug treatment, promoting progression of 
the cell cycle instead of increasing p21 to maintain the arrest. A decrease in ERCC1 
protein expression and an increase in RAD51B foci activity was observed with the 
platinum induced cell cycle arrest and did not correlate with resistance or altered 
DNA repair capacity. These changes may in part be mediating and maintaining the 
cell cycle arrest in place of p21.The rapidly proliferating resistant cells have restored 
the levels of both these proteins to their levels in untreated cells. We use the term 
‘regrowth resistance’ to describe this low-level platinum resistance where cells 
survive treatment through increased proliferation. Regrowth resistance may play a 
role in the onset of clinical resistance. 
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Chapter 
The H69CIS200 cisplatin-resistant and H69OX400 oxaliplatin-resistant small cell 
lung cancer cell lines are novel models of low-level platinum resistance (1). The 
H69CIS200 and H69OX400 cell lines were developed from parental H69 small cell 
lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml 
oxaliplatin respectively with a recovery period between treatments to emulate the 
cycles of chemotherapy given in the clinic. These cell lines are approximately 2-fold 
resistant to cisplatin and oxaliplatin and are cross resistant to both drugs. The 
resistance is not associated with increased cellular glutathione or decreased 
accumulation of platinum which are common mechanisms of platinum resistance. The 
H69 platinum sensitive cells enter a lengthy 3 week growth arrest in response to low-
level cisplatin and oxaliplatin treatment (Fig. 1A). This is an example of the 
coordinated response between the cell cycle and DNA repair. In contrast the 
H69CIS200 and H69OX400 cells have an alteration in the cell cycle allowing them to 
rapidly proliferate post drug treatment (Fig. 1B). We use the term ‘regrowth 
resistance’ to describe this low-level platinum resistance where cells survive treatment 
through increased proliferation. Regrowth resistance may play a role in the onset of 
clinical resistance.  
 
The resistant cell lines also have many chromosomal rearrangements most of which 
are not associated with the resistant phenotype, suggesting an increase in genomic 
instability in the resistant cell lines (2). The H69 cells and resistant cell lines have 
mutant p53 and consequently decrease the expression of p21 in response to platinum 
drug treatment, promoting progression of the cell cycle instead of increasing p21 to 
maintain the arrest (data not shown). We hypothesised that there was a lack of 
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coordination between the cell cycle and DNA repair in the resistant cell lines allowing 
proliferation in the presence of DNA damage which has created an increase in 
genomic instability. Increased DNA repair is a common mechanism of platinum 
resistance. However, the H69CIS200 and H69OX400 cells showed no change in DNA 
repair capacity as measured by a repair of a platinated plasmid and expression of 
DNA repair marker γH2AX (data not shown).  
 
Despite no change in DNA repair capacity in the resistant cell lines we found 
alterations in the expression and activity of two DNA repair proteins. ERCC1 is 
involved in the nucleotide excision repair removal of platinum adducts from DNA, 
increased ERCC1 mRNA and protein expression has been associated with cisplatin 
resistance (3). In contrast, we observed decreases in ERCC1 protein expression (Fig. 
2A), which were associated with the formation of a lower molecular weight band of 
approximately 26 kDa (marked with arrow Fig. 2A). We believe this to be an 
alternative spliced variant of ERCC1 associated with decreased repair activity (4). 
The samples in cell cycle arrest (grey background) had a significant decrease in 
ERCC1 protein expression compared to the untreated control cells (Fig. 2B). This 
suggests that ERCC1 expression is more related to cell cycle state than resistance. The 
samples in recovering from cell cycle arrest were not significantly different from the 
untreated control cells but had lower levels of mRNA and protein suggesting that part 
of restoring normal cell cycle activity was associated with restoring normal ERCC1 
levels. 
 
Homologous recombination repair is mediated in part by the RAD51 proteins (5). An 
increase in homologous recombination could mediate platinum resistance by 
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increasing the repair of platinum induced double-strand DNA breaks. We chose to 
examine RAD51B as it has been linked to both cell cycle control and DNA repair (6). 
We observed no change in RAD51B protein expression (data not shown). However, 
activity as measured by the presence of nuclear RAD51 foci did change. RAD51B 
foci were examined by immunocytochemistry in the H69, H69CIS200 and 
H69OX400 cell lines (Fig. 2C). The parental H69 cells had higher levels of RAD51B 
foci in response to oxaliplatin drug treatment than the H69OX400 cells. This is the 
opposite of what would be expected, since the resistant cells would be expected to 
have a higher level of repair than the sensitive parental cells. RAD51B activity was 
increased significantly in the arrested cells compared to the non-arrested controls, 
suggesting that its expression and activity are related more to the cell cycle than to 
platinum resistance. The samples in cell cycle recovery had no change in RAD51B 
foci from the untreated cells suggesting that part of restoring normal cell cycle activity 
was restoring normal RAD51B foci activity. 
 
The changes in the ERCC1 and RAD51B are associated with cell cycle arrest rather 
than resistance, suggesting that they are being modulated for reasons other than DNA 
repair and are potentially participating in the regrowth resistance mechanism of cell 
cycle arrest and recovery. There is some evidence to suggest that ERCC1 and 
RAD51B could mediate a cell cycle arrest. Hepatocytes from ERCC1 knockout mice 
are arrested in the G2 phase of the cell cycle (8). The expression of full length ERCC1 
decreases in association with the cell cycle arrest, however this is associated with the 
formation of an ERCC1 splice variant which has been previously reported to have 
reduced DNA repair activity (4). It is possible that this splice variant may have an 
increased role in the process of cell cycle arrest. Fibroblasts from ERCC1 knockout 
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mice also show a decreased rate of cell growth and disruptions in cell cycle (9) 
suggesting that the decrease in ERCC1 may contribute to the lengthy growth arrest in 
the sensitive cells. Transfection of RAD51B into CHO cells induces a cell cycle G1 
delay similar to what was observed in the H69 cells in response to platinum treatment 
(10). Transfection of RAD51 into human and rat fibroblasts also induces a G1 arrest 
(7). 
 
Resistance in the H69CIS200 and H69OX400 cells is dependent on a rapid cell cycle 
progression after drug treatment (Fig. 1B). The regrowth resistance arrest is the same 
in all cells, however, the resistant cell lines quickly exit this cell cycle arrest and 
continue to cycle despite the presence of DNA damage. Therefore the resistant cells 
have a decrease in DNA repair in response to platinum drug treatment, not because of 
a downregulation of a DNA repair pathway but because of the reduced time in cell 
cycle arrest where the repair occurs. Decreases in ERCC1 (11) and increases in 
RAD51 (12) have also been associated with increased genomic instability which 
correlate with the large amount of chromosomal aberrations found in the resistant cell 
lines (2). 
 
The normal exist from the cell cycle arrest after the successful completion of DNA 
repair is termed checkpoint recovery. Normal checkpoint recovery in the H69 parental 
cells is the 3 week growth arrest (Fig. 1A). Checkpoint adaptation is related to 
checkpoint recovery and promotes cell cycle re-entry even when unrepairable DNA 
damage is present (13). The H69CIS200 and H69OX400 cells appear to have the 
checkpoint adaptation phenotype, the cell cycle continuing despite the presence of 
DNA damage. The H69OX400 cells exit the cell cycle arrest faster than the 
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H69CIS200 cells and this correlates with the greater amount of chromosomal 
aberrations in the H69OX400 cell line (2).  
 
Conclusions 
Resistance in the H69CIS200 and H69OX400 cells is associated with the speed of the 
recovery from the cell cycle arrest, termed regrowth resistance, which may involve 
modulation of ERCC1 and RAD51B.  
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Fig. 1. Effect of acute drug treatment on cell growth and cell cycle. Cells were treated with either 1000ng/ml cisplatin 
or 2000 ng/ml oxaliplatin for 2 hours as indicated. A) The number of cells that exclude trypan blue were counted and 
the fold change in growth was plotted. B) The proportion of cells in each phase of the cell cycle was determined by 
the propidium iodide/flow cytometry.
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Fig. 2– Analysis of ERCC1 protein expression and RAD51B activity in H69, 
H69CIS200 and H69OX400 cells after a 4-day exposure either 200 ng/ml 
cisplatin or 400 ng/ml oxaliplatin. Samples in cell cycle arrest are indicated with
a gray background. A) ERCC1 protein expression determined by Western Blot 
and B) analysis in reference to the cell cycle. C) RAD51B activity determined 
by immunocytochemistry and D) analysis in reference to the cell cycle. Means 
and standard deviations are presented from pooled data from parts A and C. 
Untreated is the control cells, cell cycle arrest is the drug treated samples in cell 
arrest indicated with gray background shading, cell cycle recovery is the drug 
treated cells not in cell cycle arrest. # indicates a significant difference in 
compared to the untreated samples.
